Opportunities and challenges of generic Pre-Exposure Prophylaxis (PrEP) drugs for HIV

Written By Tim Levengood

Antiretroviral pre-exposure prophylaxis (PrEP) is protective against HIV. Low utilization rates amongst HIV vulnerable populations are due in part to the high cost of PrEP. Generic PrEP offers the potential to improve health at significantly reduced costs. In this study, we examine early utilization patterns and prices for generic PrEP. We discuss the opportunities and challenges for generic PrEP to improve health among HIV vulnerable populations.

Tim Levengood
Previous

Implementation and sustainability of safe consumption sites: a qualitative systematic review and thematic synthesis
Next

Dispensing of HIV and Hepatitis C Antivirals During COVID-19: An Interrupted Time-Series Analysis of U.S. National Data